BOSTON, Aug. 23, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that it has consummated agreements which will result in the reduction of more than $620,000 in debt for the period ending September 30, 2011. The signed settlement agreement and new consulting agreement will result in a reduction of ongoing expenses by $60,000 per quarter.
Solos Endoscopy posted its financial statements for period ended June 30, 2011. While the Company saw a modest decrease in sales over the period, Management is extremely pleased with the increase in demand for its new MammoView® instrument line.
The MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView® Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions that are undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.
"We have allocated significant resources to the development of the MammoView® instrument line. The fact that we have taken this tremendous product from concept phase to sales in dozens of hospitals across the Country is truly amazing. I'd like to thank the shareholders for all their continued support," stated Bob Segersten, President of Solos Endoscopy, Inc.
Please visit http://www.otcmarkets.com/stock/SNDY/financials  for more information.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's web